Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.

NCT04949386 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Post Acute COVID-19 Syndrome
Long COVID
COVID-19 Respiratory Infection

Interventions

DRUG: S-1226 (8%)
OTHER: Placebo

Sponsor

SolAeroMed Inc.